[Singapore]-
NDR Medical Technology, an interventional robotics company, is proud to
announce a strategic research collaboration with interventional radiologists Dr.
Sirish A. Kishore, Dr. Rajesh Shah, and the Veterans Affairs Palo Alto Health
Care System (VAPAHCS). This collaboration will benefit the large volume of
complex cancer patients at VAPAHCS and aims to validate the performance of
NDR's latest innovative automated needle targeting (ANT) technology,
specifically the NDAnalyzer and NDPathfinder AI software for percutaneous
oncologic procedures

NDAnalyzer
generates a 3D model of a patient's anatomy using CT scans and detects nodules
for biopsy or ablation, while NDPathfinder proposes a safe needle trajectory
path to target nodules while bypassing vital organs and tissues. The research
collaboration will evaluate and validate the performance of NDR's ANT-C
AI-based medical software for planning transthoracic needle placements in lung
biopsies.

"Through
this collaboration, we aim to push the boundaries of medical technology and
bring cutting-edge solutions to patients," said Alan Goh, CEO and
Co-Founder of NDR Medical. " This partnership goes beyond validating the
capabilities of the software in detecting cancer nodules and the planning of an
optimal trajectory access path. It represents our commitment to advance this
technology in the US market, as we strive to improve patient outcomes and
transform the world’s healthcare industry.”

Dr.
Kishore, Clinical Assistant Professor of Radiology at the Stanford University
School of Medicine, will be the Principal Investigator for this study. He highlights,
"As medical technology continues to support more advanced and complex
image-guided procedures, AI has great potential to advance interventional
radiology and image-guided surgery.&nbsp; For
percutaneous oncology procedures such as biopsy and ablation, for example, we
are eager to explore the potential benefits in efficiency and accuracy of target
identification and path planning. I am excited to be a part of this
collaborative effort with NDR Medical to develop the most advanced technologies
in medical AI and robotics."

Upon
completion of this retrospective study, the parties intend to develop further
collaboration in terms of prospective studies, culminating in AI-empowered
robotic assisted needle placements for targeted biopsies and other procedural
indications such as therapeutic tumor ablation.

<h1>Singapore MedTech Startup Launches Strategic Research Collaboration with Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System</h1>Strategic Research Collaboration initiated with Clinicians from Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System[Singapore]-
NDR Medical Technology, an interventional robotics company, is proud to
announce a strategic research collaboration with interventional radiologists Dr.
Sirish A. Kishore, Dr. Rajesh Shah, and the Veterans Affairs Palo Alto Health
Care System (VAPAHCS). This collaboration will benefit the large volume of
complex cancer patients at VAPAHCS and aims to validate the performance of
NDR's latest innovative automated needle targeting (ANT) technology,
specifically the NDAnalyzer and NDPathfinder AI software for percutaneous
oncologic proceduresNDAnalyzer
generates a 3D model of a patient's anatomy using CT scans and detects nodules
for biopsy or ablation, while NDPathfinder proposes a safe needle trajectory
path to target nodules while bypassing vital organs and tissues. The research
collaboration will evaluate and validate the performance of NDR's ANT-C
AI-based medical software for planning transthoracic needle placements in lung
biopsies."Through
this collaboration, we aim to push the boundaries of medical technology and
bring cutting-edge solutions to patients," said Alan Goh, CEO and
Co-Founder of NDR Medical. " This partnership goes beyond validating the
capabilities of the software in detecting cancer nodules and the planning of an
optimal trajectory access path. It represents our commitment to advance this
technology in the US market, as we strive to improve patient outcomes and
transform the world’s healthcare industry.”Dr.
Kishore, Clinical Assistant Professor of Radiology at the Stanford University
School of Medicine, will be the Principal Investigator for this study. He highlights,
"As medical technology continues to support more advanced and complex
image-guided procedures, AI has great potential to advance interventional
radiology and image-guided surgery.&nbsp; For
percutaneous oncology procedures such as biopsy and ablation, for example, we
are eager to explore the potential benefits in efficiency and accuracy of target
identification and path planning. I am excited to be a part of this
collaborative effort with NDR Medical to develop the most advanced technologies
in medical AI and robotics."Upon
completion of this retrospective study, the parties intend to develop further
collaboration in terms of prospective studies, culminating in AI-empowered
robotic assisted needle placements for targeted biopsies and other procedural
indications such as therapeutic tumor ablation.About NDR Medical Technology

NDR Medical Technology was founded in 2015 and developed the patented Automated Needle Targeting system (ANT) that can facilitate safe and accurate needle punctures to organs such as the lungs, kidney, pancreas, and spine. Integrating AI and robotics, we empower surgeons to conduct pioneer image-guided robotic procedures with improved accuracy, precision, and safety for patients.

Our first interventional robot (ANT-X) integrates C-arm fluoroscopy and AI software to assist clinicians in percutaneous needle placements and can be used in a wide range of procedures such as urology, neurology, and orthopedics. ANT-C is a smart lesion targeting system that AI uses CT-can images to automate lesion detection, needle path planning and needle targeting with unparalleled precision and accuracy. Applications include usages in pulmonology and hepatology. As a cut above the rest, our robots cost less than half of the current technology out in the market and can function without the need for external sensors.

With a renewed vision to lead AI-empowered interventional robotics, we strive to create revolutionary breakthroughs in the industry and transform the healthcare landscape.Evangeline Chia
evangeline@ndrmedical.com

Medical / Hospital

STEM (Science, Tech, Engineering, Math)

Local companies

Startups

Strategic Research Collaboration initiated with Clinicians from Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System

Singapore MedTech Startup Launches Strategic Research Collaboration with Stanford University School of Medicine and the Veterans Affairs Palo Alto Health Care System

Singapore – 28 June 2023 – NDR Medical Technology, an AI-empowered interventional robotics company, today announced that the ANT-X has been granted FDA 510(k) clearance by the U.S. Food and Drug Administration (FDA). This clearance makes ANT-X the world’s first automated robotic device to aid in needle positioning and alignment to access the kidney for Percutaneous Nephrolithotomy (PCNL), a urology procedure for kidney stone removal. It is designed to empower clinicians to perform image-guided Fluoroscopic percutaneous access with speed and precision.

Improving treatment outcomes for patients with kidney stones

Approximately 10 percent of the American population is affected by kidney stones in their lifetime1, and there is a pressing need for effective treatment. Among treatment options available for patients, PCNL stands out as the preferred treatment of choice for patients2, as it tends to see higher stone-free rates compared with procedures such as ureteroscopy3. Despite its benefits, PCNL represents only an estimated 7-8 percent of stone procedures conducted in the US today 4. With FDA approval secured for the ANT-X, clinicians will be able to carry out PCNL procedures safely and effectively for a larger number of patients.

“As urologists, we recognise that achieving percutaneous access to the renal collecting system is a crucial step that significantly impacts the success of kidney stone surgery,” said Dr Kazumi Taguchi, Assistant Professor and head of research of Nephro-urology at Nagoya City University, “Despite advancements in surgical techniques, we are still faced with the daunting task of performing this procedure, which demands considerable time and effort.”

With the advancement of PCNL techniques such as mini PCNL and ultra-mini PCNL, more patients can be discharged on the same day without the need for stents, tubing, or any remaining stones5.

"Recent trends show an increase in the use of PCNL targeting stones up to 2cm, while Mini PCNL has been proven to minimise adverse events. We are confident that the adoption of ANT-X reduces the complexity of such procedures.” said Alan Goh, CEO, NDR Medical Technology.

In the US, current reimbursement codes cover procedures for stone sizes up to 2cm or larger, with new updates to the codes allowing urologists to be incentivised for performing their own access in PCNL procedures6. With ANT-X, urologists can now confidently perform image-guided access, which was previously challenging without assistance.

NDR Medical Technology also recently placed second in the MedTech category at SelectUSA Tech 2021, a showcase for entrepreneurs at the SelectUSA Investment Summit 2021, organised by the US Department of Commerce.

Unlocking new possibilities in the future of healthcare

Beyond urology procedures, the versatility of ANT-X extends to other indications. In Singapore, the company successfully conducted its first Neurospine procedure, discoplasty, in June 2023. Driven by a vision to revolutionise the standard of care, NDR Medical Technology is seeking partners and investors to join in the mission of creating breakthrough solutions that transform the future of healthcare.

“Achieving FDA 510(k) approval gives NDR Medical Technology access to the largest healthcare market in the world, and is a critical step ahead for the company,” said Hsien-Hui Tong, Executive Director – Investments, SGInnovate. “This milestone is a sign of consistent good traction made by the team as it continues to expand the applications of its technology, and deliver value to its customers, partners and investors.”

<h1>NDR Medical Technology’s ANT-X Granted FDA Clearance, Paving the Way for Image-guided Surgeries</h1>ANT-X is an interventional robot that leverages C-arm fluoroscopy to help clinicians achieve swift and accurate percutaneous needle placement.Singapore – 28 June 2023 – NDR Medical Technology, an AI-empowered interventional robotics company, today announced that the ANT-X has been granted FDA 510(k) clearance by the U.S. Food and Drug Administration (FDA). This clearance makes ANT-X the world’s first automated robotic device to aid in needle positioning and alignment to access the kidney for Percutaneous Nephrolithotomy (PCNL), a urology procedure for kidney stone removal. It is designed to empower clinicians to perform image-guided Fluoroscopic percutaneous access with speed and precision.Improving treatment outcomes for patients with kidney stonesApproximately 10 percent of the American population is affected by kidney stones in their lifetime1, and there is a pressing need for effective treatment. Among treatment options available for patients, PCNL stands out as the preferred treatment of choice for patients2, as it tends to see higher stone-free rates compared with procedures such as ureteroscopy3. Despite its benefits, PCNL represents only an estimated 7-8 percent of stone procedures conducted in the US today 4. With FDA approval secured for the ANT-X, clinicians will be able to carry out PCNL procedures safely and effectively for a larger number of patients.“As urologists, we recognise that achieving percutaneous access to the renal collecting system is a crucial step that significantly impacts the success of kidney stone surgery,” said Dr Kazumi Taguchi, Assistant Professor and head of research of Nephro-urology at Nagoya City University, “Despite advancements in surgical techniques, we are still faced with the daunting task of performing this procedure, which demands considerable time and effort.”Increased market size in the USWith the advancement of PCNL techniques such as mini PCNL and ultra-mini PCNL, more patients can be discharged on the same day without the need for stents, tubing, or any remaining stones5."Recent trends show an increase in the use of PCNL targeting stones up to 2cm, while Mini PCNL has been proven to minimise adverse events. We are confident that the adoption of ANT-X reduces the complexity of such procedures.” said Alan Goh, CEO, NDR Medical Technology.In the US, current reimbursement codes cover procedures for stone sizes up to 2cm or larger, with new updates to the codes allowing urologists to be incentivised for performing their own access in PCNL procedures6. With ANT-X, urologists can now confidently perform image-guided access, which was previously challenging without assistance.NDR Medical Technology also recently placed second in the MedTech category at SelectUSA Tech 2021, a showcase for entrepreneurs at the SelectUSA Investment Summit 2021, organised by the US Department of Commerce.Unlocking new possibilities in the future of healthcareBeyond urology procedures, the versatility of ANT-X extends to other indications. In Singapore, the company successfully conducted its first Neurospine procedure, discoplasty, in June 2023. Driven by a vision to revolutionise the standard of care, NDR Medical Technology is seeking partners and investors to join in the mission of creating breakthrough solutions that transform the future of healthcare.“Achieving FDA 510(k) approval gives NDR Medical Technology access to the largest healthcare market in the world, and is a critical step ahead for the company,” said Hsien-Hui Tong, Executive Director – Investments, SGInnovate. “This milestone is a sign of consistent good traction made by the team as it continues to expand the applications of its technology, and deliver value to its customers, partners and investors.”
NDR Medical Technology was founded in 2015 and developed the patented Automated Needle Targeting system (ANT) that can facilitate safe and accurate needle punctures to organs such as the lungs, kidney, pancreas, and spine. Integrating AI and robotics, we empower surgeons to conduct pioneer image-guided robotic procedures with improved accuracy, precision, and safety for patients.

Our first interventional robot (ANT-X) integrates C-arm fluoroscopy and AI software to assist clinicians in percutaneous needle placements and can be used in a wide range of procedures such as urology, neurology, and orthopedics. ANT-C is a smart lesion targeting system that AI uses CT-can images to automate lesion detection, needle path planning and needle targeting with unparalleled precision and accuracy. Applications include usages in pulmonology and hepatology. As a cut above the rest, our robots cost less than half of the current technology out in the market and can function without the need for external sensors.

With a renewed vision to lead AI-empowered interventional robotics, we strive to create revolutionary breakthroughs in the industry and transform the healthcare landscape.Evangeline Chia
evangeline@ndrmedical.com

Legal / Patent / Intellectual Property

ANT-X is an interventional robot that leverages C-arm fluoroscopy to help clinicians achieve swift and accurate percutaneous needle placement.